Skip to content

Study · Ex vivo tissue · 2012

4 results

Development of an analytical HPLC methodology to study the effects of thymosin β4 on actin in sputum of cystic fibrosis patients.

Badamchian M, Damavandy AA, Goldstein AL

Annals of the New York Academy of Sciences1 Oct 2012

PMID23050822 (opens in a new tab)DOI10.1111/j.1749-6632.2012.06671.x (opens in a new tab)PepBankPUB-23050822
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    In sputum from patients with cystic fibrosis, thymosin beta‑4 increased the depolymerization of F-actin in a dose-dependent fashion, as did DNase and gelsolin each.

    In plain wordsIn lab tests of cystic fibrosis sputum, thymosin beta‑4 broke down more F-actin as the dose rose.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseF-actin depolymerization in cystic fibrosis sputum
    Study

    humann: not reported in source

    sputum from cystic fibrosis patients
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tβ4, DNase, and gelsolin each increase the depolymerization of F-actin in CF sputum in a dose-dependent fashion
    1 context sentence
    Summary · context
    The F- and G-actin content in sputum from healthy controls and cystic fibrosis (CF) patients were measured by HPLC before and after incubation with Tβ4, DNase, and gelsolin.
  2. 02LabIn vitro (cell-free)Mechanism

    In purified bovine and rabbit actin, thymosin beta‑4 depolymerized F-actin in a dose- and time-dependent manner.

    In plain wordsIn lab tests with purified actin, thymosin beta‑4 broke down F-actin filaments, and more so with higher dose and longer time.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseF-actin depolymerization
    Study

    n: not reported in source

    bovine and rabbit F- and G-actin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    F- and G-actin were incubated with thymosin β4 (Tβ4) and DNase and then analyzed by HPLC, which indicated that Tβ4 and DNase inhibit G-actin polymerization and that Tβ4 depolymerizes F-actin in a dose- and time-dependent manner.
    1 context sentence
    Summary · context
    Using bovine and rabbit F- and G-actin, this methodology results in both fractions as being well-resolved peaks, which were confirmed by dot blot immunoassay and fluorescence microscopy.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 03LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueMechanism

    In sputum from patients with cystic fibrosis, the combination of thymosin beta‑4, DNase and gelsolin had an additive effect on F-actin depolymerization.

    In plain wordsIn lab tests of cystic fibrosis sputum, thymosin beta‑4, DNase and gelsolin together broke down F-actin in an additive way.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseF-actin depolymerization by combined agents in cystic fibrosis sputum
    Study

    humann: not reported in source

    sputum from cystic fibrosis patients
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    that is additive when these agents are combined.
    1 context sentence
    Summary · context
    The F- and G-actin content in sputum from healthy controls and cystic fibrosis (CF) patients were measured by HPLC before and after incubation with Tβ4, DNase, and gelsolin.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    In purified actin, thymosin beta‑4 and DNase, reported together, inhibited G-actin polymerization.

    In plain wordsIn lab tests with purified actin, thymosin beta‑4 and DNase together were reported to block G-actin from forming filaments.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseG-actin polymerization
    Study

    n: not reported in source

    bovine and rabbit F- and G-actin
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    F- and G-actin were incubated with thymosin β4 (Tβ4) and DNase and then analyzed by HPLC, which indicated that Tβ4 and DNase inhibit G-actin polymerization and that Tβ4 depolymerizes F-actin in a dose- and time-dependent manner.
    1 context sentence
    Summary · context
    Using bovine and rabbit F- and G-actin, this methodology results in both fractions as being well-resolved peaks, which were confirmed by dot blot immunoassay and fluorescence microscopy.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.